How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics, Inc. (NASDAQ:OBLN) issued its quarterly earnings results on Thursday, March, 11th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.11. The company earned $0.06 million during the quarter. Obalon Therapeutics had a negative trailing twelve-month return on equity of 161.38% and a negative net margin of 776.76%.

When did Obalon Therapeutics' stock split?

Obalon Therapeutics shares reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Obalon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO) , Nabriva Therapeutics (NBRV) , OPKO Health (OPK) , Vaxart (VXRT) , Actinium Pharmaceuticals (ATNM) , Co-Diagnostics (CODX) , NIO (NIO) , Novavax (NVAX) and Onconova Therapeutics (ONTX) .

When did Obalon Therapeutics IPO?

Obalon Therapeutics (OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

NASDAQ:OBLN

Obalon Therapeutics (OBLN) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Free OBLN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.16
▼
$0.17
50-Day Range: $2.36
▼
$7.64
52-Week Range: $0.66
▼
$10.77

Volume: 243,173 shs
Average Volume: 7.68 million shs
Market Capitalization: $1.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Insider Trades Social Media

Get Obalon Therapeutics alerts:

Ad Paradigm Press

Biden out June 13; Kamala won’t replace him?

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

See who it is HERE.

About Obalon Therapeutics Stock (NASDAQ:OBLN)

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.

Ad Paradigm Press

Biden out June 13; Kamala won’t replace him?

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

See who it is HERE.

OBLN Stock News Headlines

February 25, 2024 | thestreet.com

Obalon Therapeutics, Inc.

February 6, 2024 | wsj.com

Spero Therapeutics Inc.

April 18, 2024 | Daily Market Alerts (Ad)

Top 5 Tech Stocks to Buy for 2024

Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.

March 28, 2023 | marketwatch.com

Intragastric Balloon Market Growth and Forecast till 2031

August 17, 2022 | marketwatch.com

Intragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 Pages

January 5, 2022 | investing.com

Renovare Environmental Inc (RENO)

August 10, 2021 | benzinga.com

Understanding Atara Biotherapeutics's Unusual Options Activity

See More Headlines

Receive OBLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Obalon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2021
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & Medical Instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:OBLN
CUSIP: N/A
CIK: 1427570
Web: www.obalon.com
Phone: (844) 362-2566
Fax: N/A
Employees: 2
Year Founded: 2008

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,330,000.00
Net Margins: -776.76%
Pretax Margin: N/A
Return on Equity: -161.38%
Return on Assets: -83.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.86
Quick Ratio: 1.86

Sales & Book Value

Annual Sales: $1.59 million
Price / Sales: 1.03
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 0.27

Miscellaneous

Outstanding Shares: 10,022,000
Free Float: N/A
Market Cap: $1.64 million
Optionable: Not Optionable
Beta: -1.23

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Andrew P. Rasdal (Age 63)
CEO, Pres & Director
Comp: $160.31k
Ms. Nooshin Hussainy (Age 63)
CFO & Sec.
Comp: $140.29k
Dr. Kelly Huang Ph.D. (Age 52)
Consultant

Key Competitors

View All Competitors

OBLN Stock Analysis - Frequently Asked Questions

How were Obalon Therapeutics' earnings last quarter?: Obalon Therapeutics, Inc. (NASDAQ:OBLN) issued its quarterly earnings results on Thursday, March, 11th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.11. The company earned $0.06 million during the quarter. Obalon Therapeutics had a negative trailing twelve-month return on equity of 161.38% and a negative net margin of 776.76%.
When did Obalon Therapeutics' stock split?: Obalon Therapeutics shares reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Obalon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), OPKO Health (OPK), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Co-Diagnostics (CODX), NIO (NIO), Novavax (NVAX) and Onconova Therapeutics (ONTX).
When did Obalon Therapeutics IPO?: Obalon Therapeutics (OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

This page (NASDAQ:OBLN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Obalon Therapeutics (OBLN) Stock Price, News & Analysis

About Obalon Therapeutics Stock (NASDAQ:OBLN)

OBLN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

OBLN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info